Open AccessTargeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Author(s) -
Ecaterina E. Dumbrava,
Kavitha Balaji,
Kanwal Raghav,
Kenneth R. Hess,
Milind Javle,
Mariela Blum-Murphy,
Jaffer A. Ajani,
Scott Kopetz,
Russell R. Broaddus,
Mark J. Routbort,
Mehmet Esat Demirhan,
Xiaofeng Zheng,
Shubham Pant,
Apostolia M. Tsimberidou,
Vivek Subbiah,
David S. Hong,
Jordi Rodón,
Kenna M. Shaw,
Sarina A. Piha-Paul,
Funda MericBernstam
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00345
Subject(s) - targeted therapy , oncology , medicine , hazard ratio , breast cancer , metastatic breast cancer , cancer , colorectal cancer , confidence interval
Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known about the prevalence of ERBB2 ( HER2 ) amplification and the efficacy of HER2-targeted treatment in other tumors.